Lv5
1250 积分 2023-06-29 加入
A way to resource is a big power to success.
Glucagon-like peptide-1 Receptor Agonists and the Cardiorenal Axis in Type 2 Diabetes: A Focus On Dulaglutide
1个月前
已关闭
Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
1个月前
已完结
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
2个月前
已完结
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2个月前
已完结
Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
2个月前
已完结
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
2个月前
已完结
Pathophysiology of Obesity
2个月前
已完结
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
2个月前
已完结
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
3个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
3个月前
已完结
皖公网安备34019202002308
